Detailed Narrative
Q1 FY27 Performance Overview
Advanced Enzyme Technologies reported a softer start to the fiscal year with consolidated revenue at INR 1,898 million, a modest 2% YoY growth but a 7% sequential decline. EBITDA stood at INR 510 million, declining 10% YoY and 19% QoQ, resulting in a moderated EBITDA margin of 27%. Profit after tax was INR 386 million, down 5% YoY and 15% sequentially, with a PAT margin of 20%. The company emphasized evaluating performance on an annual horizon due to inherent business volatility.
Impact of Sales Reversal
The quarter's revenue was significantly impacted by an additional sales reversal of INR 100 million, beyond the usual quarterly reversals. This was attributed to revenue recognition principles for goods in transit not yet delivered to customers. Management clarified that this revenue has since been recorded as of the call date, maintaining the robustness of the underlying revenue pipeline. With this adjustment, the Q1 growth would have been approximately 8%.
Segmental Performance
Human Healthcare, contributing 60% of total revenue, saw a 7% YoY and 11% sequential decline, primarily due to lower Pharma API sales, though B2C revenue in the USA improved. Animal Healthcare revenue declined 3% YoY but grew 1% QoQ to INR 252 million. Bioprocessing reported strong 30% YoY growth, reaching INR 306 million, driven by the Food business. Specialized Manufacturing showed robust performance with 41% YoY growth and an 11% QoQ increase, contributing INR 200 million.
Capital Allocation and M&A
The Board approved a buyback of INR 697 million at a ceiling price of INR 500 per share via the open market route, involving 1.4 million shares. Additionally, the company acquired the remaining 4.28% stake in its subsidiary JC Biotech for INR 79.79 million, making it a wholly-owned subsidiary. A total capex of INR 123 crores is planned for FY27, with INR 50 crores allocated to R&D and the balance for growth, as capacity utilization is currently at 70-75%.
US Market Challenges and Strategy
The US market has been a point of concern, with the company's growth being muted despite the overall market expansion. Management attributed this to geopolitical situations, logistics issues, and a strategic shift towards branding products rather than being a commodity player. They aim for 8-10% growth in the US business by the end of the year, focusing on niche segments and a revamped business model to achieve sustained growth and intact margins.
Margin and Growth Outlook
Management expects EBITDA margins to recover to the 'normal level' of 30-32% from Q2 onwards, driven by improved operational efficiency and controlled costs. Despite the soft Q1, the company remains confident in achieving double-digit revenue growth for the full fiscal year. Good growth is specifically expected from the biocatalysis segment in the second half of the year, contributing to the overall positive outlook.
R&D and New Product Development
The company spent INR 90 million on R&D in Q1, representing 4.75% of revenue, with INR 50 crores allocated for R&D capex in FY27. While new product development is ongoing across various industries like food, protein solubilization, animal feed, and detergents, management was vague about specific new products driving future growth, stating it would be a 'combination' of efforts. The novel food application approval is still pending with EFSA, expected in 3-6 months.